Metagenomi Therapeutics (MGX) Long-Term Investments (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Long-Term Investments for 4 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments rose 66.72% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 66.72% YoY), while the FY2025 annual figure was $2.2 million, down 37.51% from the prior year.
• Long-Term Investments steadied at $2.2 million in Q1 2026 per MGX's latest filing, from $2.2 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $10.6 million in Q3 2024 and bottomed at $1.3 million in Q1 2025.
• Historically, Long-Term Investments has averaged $5.6 million across 4 years, with a median of $5.7 million in 2023.
• Annual changes were most pronounced in 2025 — Long-Term Investments tumbled 84.84% — and 2026, when it soared 66.72%.
• Metagenomi Therapeutics' Long-Term Investments stood at $8.5 million in 2023, then sank by 59.55% to $3.4 million in 2024, then tumbled by 37.51% to $2.2 million in 2025, then changed by 0.0% to $2.2 million in 2026.
• Business Quant data shows MGX's Long-Term Investments at $2.2 million in Q1 2026, $2.2 million in Q4 2025, and $2.2 million in Q3 2025.